Buyback yield (TTM)
0.07%
Shareholder yield (TTM)
1.67%
5Y share count change
19.0%
Buyback spend (TTM)
$211.58M
Cumulative buybacks
$29.27B
Key takeaways
- AstraZeneca (AZN) repurchased about $211.58M of stock over the trailing twelve months.
- Diluted share count is up 19.0% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM repurchases used about 7% of free cash flow remaining after dividends.
Dividend & buyback yield over time for AstraZeneca (AZN)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for AstraZeneca (AZN)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for AstraZeneca (AZN)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for AstraZeneca (AZN)
Latest: $0.00
Overview
2025's annual buyback spend for AstraZeneca (AZN) came in at $0.00.
Between 2011 and 2025, AstraZeneca buyback spend plunged 100.0%, falling from $6.01B to $0.00.
The highest annual buyback spend of $6.01B was reported in 2011. The lowest in the available history was $0.00 in 1990.
AstraZeneca Buyback Spend 2025: $0.00
AstraZeneca buyback spend in 2025 was $0.00.
AstraZeneca Buyback Spend 2024: $0.00
AstraZeneca buyback spend in 2024 was $0.00.
AstraZeneca Buyback Spend 2023: $0.00
AstraZeneca buyback spend in 2023 was $0.00.
AstraZeneca Buyback Spend 2022: $0.00
AstraZeneca buyback spend in 2022 was $0.00.
AstraZeneca Buyback Spend 2021: $0.00
AstraZeneca buyback spend in 2021 was $0.00.
See more financial history for AstraZeneca (AZN).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $0.00 | $0.00 | $0.00 | — | 1.56B | -0.1% | |
| 2024 | $0.00 | $0.00 | $0.00 | — | 1.56B | +0.1% | |
| 2023 | $0.00 | $579.00M | −$579.00M | — | 1.56B | +0.1% | |
| 2022 | $0.00 | $619.00M | −$619.00M | — | 1.56B | +9.3% | |
| 2021 | $0.00 | $615.00M | −$615.00M | — | 1.43B | +8.7% | |
| 2020 | $0.00 | $277.00M | −$277.00M | — | 1.31B | +0.9% | |
| 2019 | $0.00 | $259.00M | −$259.00M | — | 1.30B | +2.7% | |
| 2018 | $0.00 | $0.00 | $0.00 | — | 1.27B | 0.0% | |
| 2017 | $0.00 | $0.00 | $0.00 | — | 1.27B | +0.1% | |
| 2016 | $0.00 | $0.00 | $0.00 | — | 1.27B | +0.1% | |
| 2015 | $0.00 | $0.00 | $0.00 | — | 1.26B | +0.1% | |
| 2014 | $0.00 | $0.00 | $0.00 | — | 1.26B | +0.8% | |
| 2013 | $0.00 | $0.00 | $0.00 | — | 1.25B | -0.8% | |
| 2012 | $2.63B | $0.00 | $2.63B | 4.47% | 1.26B | -7.5% | |
| 2011 | $6.01B | $0.00 | $6.01B | 9.90% | 1.37B | -5.5% | |
| 2010 | $2.60B | $0.00 | $2.60B | 3.98% | 1.45B | -0.3% | |
| 2009 | $0.00 | $0.00 | $0.00 | — | 1.45B | -0.2% | |
| 2008 | $610.00M | $0.00 | $610.00M | 1.03% | 1.45B | -3.0% | |
| 2007 | $4.17B | $0.00 | $4.17B | 6.68% | 1.50B | -4.6% | |
| 2006 | $4.15B | $0.00 | $4.15B | 5.10% | 1.57B | -3.0% | |
| 2005 | $3.00B | $0.00 | $3.00B | 3.91% | 1.62B | -3.3% | |
| 2004 | $2.21B | $0.00 | $2.21B | 3.67% | 1.67B | -2.1% | |
| 2003 | $1.11B | $0.00 | $1.11B | 1.38% | 1.71B | -1.5% | |
| 2002 | $1.15B | $0.00 | $1.15B | 1.92% | 1.74B | -1.3% | |
| 2001 | $1.08B | $0.00 | $1.08B | 1.33% | 1.76B | -0.6% | |
| 2000 | $353.98M | $0.00 | $353.98M | — | 1.77B | -0.5% | |
| 1999 | $183.00M | $0.00 | $183.00M | — | 1.78B | +90.2% | |
| 1998 | $0.00 | $0.00 | $0.00 | — | 0.93B | -1.8% | |
| 1997 | $0.00 | $0.00 | $0.00 | — | 0.95B | +0.4% | |
| 1996 | $0.00 | $0.00 | $0.00 | — | 0.95B | — | |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1990 | $0.00 | $0.00 | $0.00 | — | — | — |
- 2025$0.00
- 2024$0.00
- 2023$0.00
- 2022$0.00
- 2021$0.00
- 2020$0.00
- 2019$0.00
- 2018$0.00
- 2017$0.00
- 2016$0.00
- 2015$0.00
- 2014$0.00
- 2013$0.00
- 2012$2.63B
- 2011$6.01B
- 2010$2.60B
- 2009$0.00
- 2008$610.00M
- 2007$4.17B
- 2006$4.15B
- 2005$3.00B
- 2004$2.21B
- 2003$1.11B
- 2002$1.15B
- 2001$1.08B
- 2000$353.98M
- 1999$183.00M
- 1998$0.00
- 1997$0.00
- 1996$0.00
- 1995$0.00
- 1994$0.00
- 1993$0.00
- 1992$0.00
- 1991$0.00
- 1990$0.00
Buybacks vs stock-based compensation for AstraZeneca (AZN)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: N/A.
Buybacks vs dividends (share of cash returned) for AstraZeneca (AZN)
How AstraZeneca splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as AstraZeneca, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $3.00B | |
| $980.00M | |
| $216.35M | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $3.18B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation